Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lexicon Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults ≥18 years of age
Documented diagnosis of POAG or OHT, in both eyes
Willing and able to provide written informed consent
You may not be if
History of any form of glaucoma in either eye, other than POAG
Subjects who are unwilling or unable to discontinue contact lens wear prior to and during study
History of ocular trauma in either eye \<6 months prior to Screening
History of ocular infection or ocular inflammation in either eye \<3 months prior to Screening
History of chronic or recurrent severe inflammatory eye disease, any severe ocular pathology, or clinically relevant or progressive retinal diseases in either eye
Clinically relevant, severe central visual field loss, or documented significant progression of a visual field defect within 6 months prior to Screening in either eye
Use of any ocular hypertensive medications (if applicable), in either eye, during the washout period and for the duration of the study
Use of any glucocorticoid medications \<2 weeks prior to Screening and throughout the duration of the study
Use of any medication or substance on a chronic basis which has not been taken at a stable dose for at least 30 days prior to Screening
Use of any nondiagnostic, topical, ophthalmic preparations, in either eye, other than artificial tears
The presence of any concurrent condition or clinically significant laboratory findings at Screening that may interfere with any aspect of safety, study conduct, or interpretation of results
Women who are pregnant or breast feeding
Inability or difficulty instilling eye drops
Clareo Health | Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
